Abigail Lewis, Content Intern

Cerebral visual impairment is now the leading cause of childhood vision loss. Three experts explain the history, science, and clinical signs eye care providers need to know.

Elkins shares the moving realities of volunteering with Remote Area Medical, from patients lining up before dawn to what it takes for an OD to get involved.

In this Q&A, LENZ CFO Dan Chevallard on Vizz's ECP momentum, telehealth expansion, and the global push to end reading glasses for presbyopia.

The new patient, secured by Provectus and VisiRose, supports a light-independent rose bengal eye drop that fights MRSA and other drug-resistant keratitis, erases biofilms, and enables self-administered treatment.

A midyear look at 2026's biggest optometry findings, from myopia control research to safety signals on red light therapy and semaglutide.

Optometry's meetings thus far reveal a field in motion: earlier glaucoma intervention, an expanding dry eye pipeline, breakthrough myopia data, and sharper contact lens and retinal evaluation.

A summary of major FDA approvals and CRLs in eye care from the first half of 2026.

Clinical trial data support the Deseyne contact lens, the first FDA-designated EDOF soft contact lens, as a new daily disposable option for presbyopia.

Preservative-free bimatoprost gel now offers once-daily glaucoma and ocular hypertension IOP reduction, aiming to boost comfort, tolerability, and long-term adherence.

Mark Wells, OD, weighs in on the new parameter range expected for the Acuvue Oasys 1-Day for Astigmatism lens.

New preservative-free cyclosporine 0.05% single-use drops target dry eye inflammation, dosing, and safety.

New phase 3 trial tests rhNGF eye drops for persistent corneal epithelial defects, aiming for full healing and a first approved PCED therapy.

The investment will expand ACUVUE contact lens manufacturing and distribution in Jacksonville, improving supply chain stability for optometrists by 2028.

Epion completes phase 3 follow-up for EpiSmart epi-on corneal cross-linking in keratoconus, advancing toward FDA NDA and a less painful alternative.

Oculis launches a genotype-guided dry eye trial testing licaminlimab eye drops, targeting TNFR1 patients and measuring Day 29 ocular discomfort improvement.

The free web-based tool guides eye care providers through evidence-based amblyopia diagnosis and treatment without requiring pediatric subspecialty training.

New findings confirm TearCare's long-term effectiveness for dry eye disease, showing significant patient improvements with minimal treatments over 2 years.

The partnership marks a major step toward expanding global access to targeted treatments for this vision-threatening condition, according to a news release.